CLRB

Cellectar Biosciences, Inc. (CLRB) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company developing cancer treatments using its proprietary Phospholipid Drug Conjugate (PDC) platform. The Company is a non-accelerated filer and a smaller reporting company. As of August 12, 2025, there were 3,192,040 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased significantly year-over-year. For the six months ended June 30, 2025, expenses were $12.44 million compared to $25.71 million in the prior year period. This 60% reduction in R&D and 41% reduction in G&A was driven by the conclusion of patient enrollment in the CLOVER WaM Phase 2b clinical trial and reduced pre-commercialization activities.
• Net Loss Improvement: The net loss for the six months ended June 30, 2025, was $12.05 million, a substantial improvement from the $27.56 million loss in the same period in 2024. This improvement is largely attributed to a non-cash gain on the valuation of warrants in 2025 ($161,598) compared to a significant loss in 2024 ($2.5 million), alongside reduced operating costs.
• Liquidity Position: Cash and cash equivalents declined from $23.29 million at year-end 2024 to $11.04 million at June 30, 2025, reflecting a net decrease of $12.25 million primarily due to operating cash outflows.
• Capital Structure: The Company executed a 1:30 reverse stock split effective June 24, 2025, to maintain Nasdaq listing standards. Additionally, warrant exercises in June 2025 generated approximately $2.5 million in gross proceeds.

Guidance, Outlook, and Risks

• Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. Management estimates available liquidity of approximately $15 million, which may be insufficient to fund operations beyond the second quarter of 2026 without additional capital.
• Strategic Alternatives: On April 30, 2025, the Company announced it is exploring strategic alternatives, including mergers, acquisitions, partnerships, or licensing arrangements, to advance its pipeline.
• Regulatory Milestones: On June 4, 2025, the FDA granted Breakthrough Therapy Designation for iopofosine I 131 for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM). The Company plans to submit an NDA for accelerated approval, contingent on funding for a confirmatory Phase 3 trial.
• Pipeline Updates: The Company plans to initiate a Phase 1b dose-finding study for CLR 125 (iodine-125) and a Phase 1 imaging study for CLR 225 (actinium-225) in the second half of 2025, subject to securing additional financing.
• Internal Controls: Management identified material weaknesses in internal control over financial reporting related to the accounting of preferred equity, warrants, and stock-based compensation. These weaknesses led to restatements of prior periods and remain unremediated as of June 30, 2025.
• Subsequent Event: On July 2, 2025, the Company completed an underwritten public offering raising approximately $6.9 million in gross proceeds.

Investor Verification Checklist

• Verify the sufficiency of the $6.9 million raised in the July 2025 offering to fund the proposed Phase 3 confirmatory trial for iopofosine I 131 and the Phase 1b study for CLR 125.
• Confirm the timeline and specific terms of any strategic partnership or transaction announced following the April 30, 2025 exploration of alternatives.
• Review the progress of remediation efforts regarding the material weaknesses in internal controls over financial reporting.
• Monitor the FDA's response to the Company's End-of-Phase-2 meeting regarding the design of the confirmatory Phase 3 trial for iopofosine I 131.
• Assess the impact of the 1:30 reverse stock split on liquidity and marketability of the common stock.